Please assess the completion status of the following clinical trial:

Trial Title: Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Department of Defense (DOD) Healthcare beneficiary~* Parasitologic diagnosis of cutaneous Leishmania infection~(Inclusion criteria for randomization includes that must be Leishmania major species)~* Willing to locate to WRAMC area during treatment and perform subsequent follow-up visits if needed~(If not active duty on orders, then the participant will bear the cost of food and lodging during the initial 10-day outpatient treatment period at Walter Reed Army Medical Center)~* Able to provide informed consent~* All participants (both male and female) must agree to take precautions not to become pregnant or father a child for at least 2 months after receiving sodium stibogluconate~Exclusion Criteria:~* Unable to provide informed consent~* Pregnancy (females of child bearing potential must have negative urine human chorionic gonadotropic hormone \[HCG\] within 48 hours of the start of infusion period)~* History of hypersensitivity to pentavalent antimonials~* Serious medical illness:~  1. QTc interval \>/= 0.5 sec~ 2. severe cardiac disease~ 3. history of current pancreatitis~ 4. liver failure or active hepatitis with transaminases \>3X normal~ 5. renal failure or creatinine \>2.5~ 6. thrombocytopenia (platelets \<75,000)~ 7. white blood cell count \<2000~ 8. hematocrit \<25~ 9. absence of palpable extremity pulses in the limb requiring treatment~* History of serious allergic reaction to local anesthetics~* Location of lesion not amenable to local therapy (such as close to eye, mucous membranes, face, cartilage)~* Presence of pacemaker and/or other implanted metallic devices~* Breast feeding~* Men unwilling to avoid fathering a child during and/or in the two months following receiving the treatment~* Women unwilling to avoid pregnancy for at least two months after receiving the treatment~* More than 20 lesions, or multiple lesions which in the opinion of the investigator would not be well treated with heat therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sodium stibogluconate intravenous (Type: ACTIVE_COMPARATOR): 20 mg/kg/day Sodium stibogluconate intravenous
- ThermoMed device (Type: EXPERIMENTAL): ThermoMed device, single heat treatment at 50 degrees Celsius

Based on this trial design, predict the completion outcome and termination type (if applicable).